For well over a decade, proton pump inhibitors (PPIs) have been considered the first-line treatment for gastroesophageal reflux disease, or GERD. In 2003, U.S. sales of the five delayed-release PPI brands totaled $12.9 billion, with total U.S. prescriptions for PPIs growing 10%, from 86.3 million in 2002 to 95.2 million in 2003, according to IMS Health.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.